본문 바로가기
KERD
논문KCI 등재

Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL

Jong Eun Yeon
대한간학회 (The korean Association for the Study of the Liver)|2018.09|Clinical and Molecular Hepatology|제24권 제3호|pp. 278-293

1

조회

0

다운로드

9

인용

0

참고문헌

키워드

GenotypeLiver cirrhosisHepatitis C virusDirect acting antiviralResistance associated substitutions

초록

The paradigm for the treatment of chronic hepatitis C (CHC) has been changed due to the development of direct acting antivirals (DAAs) of hepatitis C virus (HCV). The high sustained virologic response rate and ease of administration makes the DAAs approach ideal to contribute to the complete eradication of HCV. Currently, treatment options for individual patients vary depending on the genotype or subtype of HCV, presence or absence of liver cirrhosis, previous experience of antiviral treatment or resistance associated substitutions. Because of drug avalilability, cost-effectiveness, preference, compliance and greater possibility of desirable effects and presumed patient-important outcomes may vary between countries, treatment options for individual patients are different. The review focuses on the comparing the current treatment options for CHC in other continents with the 2017 Korea Association for the Study of the Liver guidelines.

Abstract

The paradigm for the treatment of chronic hepatitis C (CHC) has been changed due to the development of direct acting antivirals (DAAs) of hepatitis C virus (HCV). The high sustained virologic response rate and ease of administration makes the DAAs approach ideal to contribute to the complete eradication of HCV. Currently, treatment options for individual patients vary depending on the genotype or subtype of HCV, presence or absence of liver cirrhosis, previous experience of antiviral treatment or resistance associated substitutions. Because of drug avalilability, cost-effectiveness, preference, compliance and greater possibility of desirable effects and presumed patient-important outcomes may vary between countries, treatment options for individual patients are different. The review focuses on the comparing the current treatment options for CHC in other continents with the 2017 Korea Association for the Study of the Liver guidelines.

참고문헌 (59)

  1. "KASL clinical practice guidelines: management of hepatitis C", Clin Mol Hepatol, 20, pp.89~136 (2014)[DOI]
  2. "KASL clinical practice guidelines: management of hepatitis C", Clin Mol Hepatol, 22, pp.76~139 (2016)[DOI]
  3. "KASL Clinical Practice Guidelines, Management of hepatitis C: Treatment of chronic hepatitis C"[URL]
  4. "HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C"[URL]
  5. "EASL Recommendations on Treatment of Hepatitis C 2016", J Hepatol, 66, pp.153~194 (2017)[DOI]
  6. Zeuzem S, "Grazoprevir-elbasvir combination therapy for treatment-Naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial", Ann Intern Med, 163, pp.1~13 (2015)[DOI]
  7. "Hepatology", 2015, 1393~1394
  8. "Hepatology", 2016, 132A~133A
  9. "Gastroenterology", 2017, S1062~S1063
  10. Forns X, "Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial", Lancet Infect Dis, 17, pp.1062~1068 (2017)[DOI]
  11. Wyles D, "Glecaprevir", pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and, Hepatology, pp.2018, 67[DOI]
  12. Feld JJ, "Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection", N Engl J Med, 373, pp.2599~2607 (2015)[DOI]
  13. Foster GR, "Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection", N Engl J Med, 373, pp.2608~2617 (2015)[DOI]
  14. Jacobson IM, "Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials", Gastroenterology, 153, pp.113~122 (2017)[DOI]
  15. Guyatt GH, "GRADE: an emerging consensus on rating quality of evidence and strength of recommendations", BMJ, 336, pp.924~926 (2008)[DOI]
  16. Kao JH, "All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study", Liver Int, 36, pp.1433~1441 (2016)[DOI]
  17. McPhee F, "High sustained virologic response to daclatasvir plus asunaprevir in elderly and cirrhotic patients with hepatitis C virus genotype 1b without baseline NS5A polymorphisms", Adv Ther, 32, pp.637~649 (2015)[DOI]
  18. Backus LI, "Realworld effectiveness of ledipasvir", sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients, 2016, pp.64, 405~414
  19. Kowdley KV, "Eight weeks of ledipasvir", sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection, 2017, pp.65, 1094~1103
  20. Pol S, "Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-monoinfected patients", J Hepatol, 66, pp.39~47 (2017)[DOI]
  21. Afdhal N, "Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection", N Engl J Med, 370, pp.1483~1493 (2014)[DOI]
  22. Zeuzem S, "NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome", J Hepatol, 66, pp.910~918 (2017)[DOI]
  23. Lawitz E, "Sofosbuvir for previously untreated chronic hepatitis C infection", N Engl J Med, 368, pp.1878~1887 (2013)[DOI]
  24. Jacobson IM, "Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options", N Engl J Med, 368, pp.1867~1877 (2013)[DOI]
  25. Welzel TM, "Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study", Gut, 66, pp.1844~1852 (2017)[DOI]
  26. Mangia A, "Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: a real life experience", J Hepatol, 66, pp.711~717 (2017)[DOI]
  27. "Clin Mol Hepatol", 2017, 62~63
  28. Sulkowski MS, "Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection", N Engl J Med, 370, pp.211~221 (2014)[DOI]
  29. Ippolito AM, "HCV clearance after direct-acting antivials in patients with cirrhosis by stages of liver impairment: the ITAL-C network study", Dig Liver Dis, 49, pp.1022~1028 (2017)[DOI]
  30. Nelson DR, "All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study", Hepatology, 61, pp.1127~1135 (2015)[DOI]
  31. Alonso S, "Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort", J Viral Hepat, 24, pp.304~311 (2017)[DOI]
  32. Kohli A, "Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study", Lancet Infect Dis, 15, pp.1049~1054 (2015)[DOI]
  33. Abergel A, "Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection", Hepatology, 64, pp.1049~1056 (2016)
  34. "J Hepatol", 2015, S278~S279
  35. "J Hepatol", 2016, S755~
  36. Abergel A, "Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study", Lancet Infect Dis, 16, pp.459~464 (2016)[DOI]
  37. Gane EJ, "Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection", Gastroenterology, 149, pp.1454~1461 (2015)[DOI]
  38. Charlton M, "Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease", Gastroenterology, 149, pp.649~659 (2015)[DOI]
  39. Poordad F, "Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence", Hepatology, 63, pp.1493~1505 (2016)[DOI]
  40. Curry MP, "Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis", N Engl J Med, 373, pp.2618~2628 (2015)[DOI]
  41. "J Hepatol", 2017, S90~S91, 10.1016[DOI]
  42. Kwo PY, "An interferon-free antiviral regimen for HCV after liver transplantation", N Engl J Med, 371, pp.2375~2382 (2014)[DOI]
  43. Cholongitas E, "Interferon-free regimens in patients with hepatitis C infection and renal dysfunction or kidney transplantation", World J Hepatol, 9, pp.180~190 (2017)[DOI]
  44. Pockros PJ, "Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease", Gastroenterology, 150, pp.1590~1598 (2016)[DOI]
  45. Roth D, "Grazoprevir plus elbasvir in treatment-naive and treatmentexperienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study", Lancet, 386, pp.1537~1545 (2015)[DOI]
  46. Gane E, "Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment", N Engl J Med, 377, pp.1448~1455 (2017)[DOI]
  47. Toyota J, "Daclatasvir", asunaprevir, J Gastroenterol, pp.2017, 52[DOI]
  48. Akuta N, "Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens", J Med Virol, 89, pp.1248~1254 (2017)[DOI]
  49. Lawitz E, "Short-duration treatment with elbasvir", grazoprevir and sofosbuvir for hepatitis C: a randomized trial, 2017, pp.65, 439~450
  50. Poordad F, "Ombitasvir", paritaprevir, J Hepatol, pp.2016, 64(Suppl)[DOI]
  51. Bourliere M, "Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection", N Engl J Med, 376, pp.2134~2146 (2017)[DOI]
  52. Poordad F, "Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment", Hepatology, 66, pp.389~397 (2017)[DOI]
  53. "Gastroenterology", 2017, S1057~
  54. Osinusi A, "Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study", Ann Intern Med, 161, pp.634~638 (2014)[DOI]
  55. Wyles D, "Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens", Hepatology, 61, pp.1793~1797 (2015)[DOI]
  56. Wyles DL, "Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1", N Engl J Med, 373, pp.714~725 (2015)[DOI]
  57. "J Hepatol", 2017, S503~
  58. "Hepatology", 2016, 39A~
  59. "Hepatology", 2016, 1128A~, 10.1016[DOI]

관련 논문AI추천

만성 C형 간염 진료 가이드라인 비교김경아대한내과학회 · 대한내과학회지2015 · 제88권 제6호Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era김경아, 김영석, 김인희, 이병석, 이연재, 장은선, 정숙향, 청우진거트앤리버 소화기연관학회협의회 · Gut and Liver2017 · 제11권 제4호Assessing the Effectiveness and Safety of Direct-acting Antiviral Treatment in Korean Patients with Hepatitis C Virus Genotype 1b or 2 at a Tertiary Care Hospital김주신, 박기현, 박미선, 양영모, 윤현옥, 최은주한국임상약학회 · 한국임상약학회지2022 · 제32권 제3호2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis CThe Korean Association for the Study of the Liver대한간학회 · Clinical and Molecular Hepatology2018 · 제24권 제3호Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study배시현, 성필수, 양진모, 윤승규, 최종영, Chang Wook Kim, Do Seon Song, Hae Lim Lee, Heechul Nam, Hee Yeon Kim, Hyun Yang, Jaejun Lee, Jeong Won Jang, Ji Won Han, Jung Hyun Kwon, Myeong Jun Song, Seok-Hwan Kim, Soon Kyu Lee, Soon Woo Nam, Sung Won Lee, Sun Hong Yoo, U Im Chang대한내과학회 · The Korean Journal of Internal Medicine2022 · 제37권 제6호Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver CirrhosisNobuyuki Toshikuni거트앤리버 소화기연관학회협의회 · Gut and Liver2017 · 제11권 제3호

이 간행물의 다른 논문 (11건)

KASL clinical practice guidelines for liver cirrhosis: Ascites and related complicationsThe Korean Association for the Study of the Liverpp. 169-2292017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis CThe Korean Association for the Study of the Liverpp. 230-277Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?Jong Eun Yeonpp. 294-296Prognostic implications of trunk muscle mass in liver cirrhosis김원, Jimin Hanpp. 297-298Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?조용균pp. 299-301
원문 보기